Filing Details
- Accession Number:
- 0000914190-19-000488
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-12-17 16:32:44
- Reporting Period:
- 2019-12-12
- Accepted Time:
- 2019-12-17 16:32:44
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 842023 | Bio-Techne Corp | TECH | Biological Products, (No Disgnostic Substances) (2836) | 411427402 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1443851 | S. Brenda Furlow | 614 Mckinley Place Ne Minneapolis MN 55413 | Svp - General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2019-11-12 | 492 | $0.00 | 2,711 | No | 5 | G | Direct | |
| Common Stock | Acquisiton | 2019-12-12 | 8,000 | $94.35 | 10,711 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-12-12 | 426 | $214.32 | 10,285 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-12 | 3,227 | $215.17 | 7,058 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-12 | 4,147 | $216.01 | 2,911 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-12 | 200 | $216.75 | 2,711 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 5 | G | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to Buy) | Disposition | 2019-12-12 | 8,000 | $0.00 | 8,000 | $94.35 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 1,600 | 2021-08-12 | No | 4 | M | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to Buy) | $108.49 | 2022-08-07 | 10,000 | 10,000 | Direct | |
| Common Stock | Stock Options (Right to Buy) | $108.49 | 2022-08-07 | 5,995 | 5,995 | Direct | |
| Common Stock | Stock Options (Right to Buy) | $106.59 | 2023-08-18 | 10,857 | 10,857 | Direct | |
| Common Stock | Stock Options (Right to Buy) | $106.59 | 2023-08-18 | 14,476 | 14,476 | Direct | |
| Common Stock | Restricted Stock Units | $0.00 | 1,724 | 1,724 | Direct | ||
| Common Stock | Stock Options (Right to Buy) | $125.05 | 2024-08-09 | 9,503 | 9,503 | Direct | |
| Common Stock | Stock Options (Right to Buy) | $125.05 | 2024-08-09 | 12,670 | 12,670 | Direct | |
| Common Stock | Restricted Stock Units | $0.00 | 1,374 | 1,374 | Direct | ||
| Common Stock | Stock Options (Right to Buy) | $177.32 | 2025-08-08 | 7,339 | 7,339 | Direct | |
| Common Stock | Stock Options (Right to Buy) | $177.32 | 2025-08-08 | 9,786 | 9,786 | Direct | |
| Common Stock | Restricted Stock Units | $0.00 | 1,969 | 1,969 | Direct | ||
| Common Stock | Stock Options (Right to Buy) | $190.41 | 2026-08-07 | 9,968 | 9,968 | Direct | |
| Common Stock | Stock Options (Right to Buy) | $190.41 | 2026-08-07 | 13,290 | 13,290 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2022-08-07 | 10,000 | 10,000 | Direct |
| 2022-08-07 | 5,995 | 5,995 | Direct |
| 2023-08-18 | 10,857 | 10,857 | Direct |
| 2023-08-18 | 14,476 | 14,476 | Direct |
| 1,724 | 1,724 | Direct | |
| 2024-08-09 | 9,503 | 9,503 | Direct |
| 2024-08-09 | 12,670 | 12,670 | Direct |
| 1,374 | 1,374 | Direct | |
| 2025-08-08 | 7,339 | 7,339 | Direct |
| 2025-08-08 | 9,786 | 9,786 | Direct |
| 1,969 | 1,969 | Direct | |
| 2026-08-07 | 9,968 | 9,968 | Direct |
| 2026-08-07 | 13,290 | 13,290 | Direct |
Footnotes
- Represents a transfer of shares to a charitable donor advised fund. The reporting person retained no pecuniary interest in the transferred shares.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.67 to $214.66 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.69 to $215.68 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.69 to $216.53 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.71 to $216.79 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- Fully exercisable.
- Options to purchase 2,447 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 2,446 shares vest on each of 8/8/2021 and 8/8/2022.
- Options to purchase 3,167 shares vest on each of 8/9/2018 and 8/9/2019 and options to purchase 3,168 shares vest on each of 8/9/2020 and 8/9/2021.
- Options to purchase 3,323 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 3,322 shares vest on each of 8/7/2022 and 8/7/2023.
- Options to purchase 3,619 shares vest on each of 8/18/2017, 8/18/2018, 8/18/2019 and 8/18/2020.
- Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Billionaire Hedge Funds
